ReviewAmerican journal of hematology2012
Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation.
Review in American journal of hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02876211 (Benefits of the Paricalcitol), which is not on this map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Benefits of the Paricalcitol (Selective Vitamin D Receptor Activator) on Anemia of Inflammation in Dialysis Patients Under Erythropoiesis-stimulating Agents Treatment.
Who cites it
79 citing papers in PubMed, 183 citations in OpenAlex.
- Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.British journal of clinical pharmacology · 2019Trial
- Trial
- An Almond Meal-Rich Diet Improves Red Blood Cell Count and Reduces Odds of Anemia in a Mouse Model of Aging.Antioxidants (Basel, Switzerland) · 2026Article
- Intermittent oral administration of iron oxide nanoparticles modulates iron homeostasis, hematological, inflammatory, and organ-specific responses in iron-deficient rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Association of novel inflammation markers derived from high-sensitivity C-reactive protein with anemia: a cross-sectional study based on NHANES 2015-2018.Thrombosis journal · 2026Article
- Roxadustat for Erythropoiesis-Stimulating Agent Hyporesponsive Anemia in Hemodialysis: Multicenter Retrospective Analysis.Medicina (Kaunas, Lithuania) · 2026Observational
- Mechanisms driving resistance to oxidative stress during endometrial stromal cell decidualization†.Biology of reproduction · 2026Review
- Targeting hepcidin to restore oral iron efficacy after vertical sleeve gastrectomy.Frontiers in nutrition · 2026Article
- Diagnostic Significance of Serum Ferritin and Hepcidin as Complementary Biomarkers for Prostate Disease: A Prospective Case-Control Study in a Mission Hospital, Ghana.Health science reports · 2025Article
- Advances in Iron Deficiency Anaemia Management: Exploring Novel Drug Delivery Systems and Future Perspectives.Current drug delivery · 2025Review
- Inflammation alters iron distribution in bone and spleen in mice.Metallomics : integrated biometal science · 2023Article
- Pathophysiology and Treatment Opportunities of Iron Deficiency in Heart Failure: Is There a Need for Further Trials?Current heart failure reports · 2023Review
- The relationship between FGF23 and anemia in HD and renal transplant patients.International urology and nephrology · 2022Article
- Non-erythropoiesis-stimulating agent, non-iron therapies for the management of anaemia: protocol for a scoping review.BMJ open · 2022Article
- Article
- Anemia in Pediatric Kidney Transplant Recipients-Etiologies and Management.Frontiers in pediatrics · 2022Review
- Low Hemoglobin-to-Red Cell Distribution Width Ratio Is Associated with Disease Progression and Poor Prognosis in Upper Tract Urothelial Carcinoma.Biomedicines · 2021Article
- Cancer Related Anemia: An Integrated Multitarget Approach and Lifestyle Interventions.Nutrients · 2021Review
- Iron Metabolism: An Under Investigated Driver of Renal Pathology in Lupus Nephritis.Frontiers in medicine · 2021Review
- Pharmacological Targeting of BMP6-SMAD Mediated Hepcidin Expression Does Not Improve the Outcome of Systemic Infections With Intra-Or Extracellular Gram-Negative Bacteria in Mice.Frontiers in cellular and infection microbiology · 2021Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
Anemia of chronic disease (ACD) or anemia of inflammation is prevalent in patients with chronic infection, autoimmune disease, cancer, and chronic kidney disease. ACD is associated with poor prognosis and lower quality of life. Management of ACD using intravenous iron and erythropoiesis stimulating agents are ineffective for some patients and are not without adverse effects, driving the need for new alternative therapies. Recent advances in our understanding of the molecular mechanisms of iron regulation reveal that increased hepcidin, the iron regulatory hormone, is a key factor in the development of ACD. In this review, we will summarize the role of hepcidin in iron homeostasis, its contribution to the pathophysiology of ACD, and novel strategies that modulate hepcidin and its target ferroportin for the treatment of ACD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.